Strong Earnings Beat & Raised Guidance: Elevance Health reported second-quarter adjusted diluted earnings per share of $7.45, significantly exceeding Wall Street's forecast of $6.21. The company also surpassed revenue expectations, achieving $49.8 billion in operating revenue and $50.47 billion in total revenue. Reflecting this performance, full-year adjusted EPS guidance was raised to at least $27.00, and operating cash flow guidance was increased to at least $6.0 billion.
Medicaid Challenges and Strategic Exits: Despite the overall beat, Medicaid remains a significant challenge, with management describing 2026 as a trough year for margins in this segment, anticipating a negative 1.75% operating margin outlook. In response, Elevance Health plans to exit additional Medicaid markets over the next 12 to 18 months where sustainable returns are not achievable.
Carelon's Robust Performance and Strategic Investments: The Carelon segment continues to be a key growth driver, reporting $19.2 billion in operating revenue, a 6% year-over-year increase. CarelonRx showed particularly strong operating gain growth, up 8.6%. The company is also making strategic investments in AI and digital infrastructure to enhance medical cost management and improve care delivery.
Membership Dip and CMS Resolution: Total medical membership decreased by 1.5% year-over-year to 44.9 million members, attributed to Medicaid attrition and a fee-based customer transition. Positively, the company announced that the Centers for Medicare & Medicaid Services (CMS) will not impose sanctions regarding a prior Medicare Advantage risk adjustment matter, following a payment of $342 million.
Investor Skepticism Despite Beat: Elevance Health's shares fell sharply (over 10%) after the earnings report. This negative market reaction, despite exceeding earnings and revenue estimates, suggests investor concern regarding ongoing margin pressures in the Medicaid business and the impact of a reported $0.80 per-share non-recurring benefit from net investment income valuation adjustments on the adjusted EPS.

Overall Takeaway
The Q2 fiscal 2026 earnings call for Elevance Health was ultimately perceived as mixed to negative by investors. While the company delivered a clear beat on both adjusted EPS and revenue, and raised its full-year guidance, the market reaction was characterized by a significant share price drop. This indicates that investors focused more on the persistent challenges within the Medicaid segment, the decline in overall membership, and the reliance on one-time benefits to boost earnings, raising questions about the sustainability and quality of future growth.

Income Overview

Time Plot

Income Statement

Income Overview

Time Plot

Income Statement